CN103463023B - Application of Lycojaponicumin B in helicobacter pylori resistant medicine - Google Patents
Application of Lycojaponicumin B in helicobacter pylori resistant medicine Download PDFInfo
- Publication number
- CN103463023B CN103463023B CN201310435573.2A CN201310435573A CN103463023B CN 103463023 B CN103463023 B CN 103463023B CN 201310435573 A CN201310435573 A CN 201310435573A CN 103463023 B CN103463023 B CN 103463023B
- Authority
- CN
- China
- Prior art keywords
- lycojaponicumin
- helicobacter pylori
- preparation
- application
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
In-vitro activity experiments show that Lycojaponicumin B has strong helicobacter pylori (Hp) resistant activity. The Lycojaponicumin B can be applied to treatment of diseases, such as acute and chronic gastritis and gastric and duodenal ulcer, and preparation of medicines for treating the acute and chronic gastritis and the gastric and duodenal ulcer. The application of the Lycojaponicumin B in preparation of the Hp resistant medicine is disclosed for the first time. The skeleton type of the Lycojaponicumin B belongs to a brand-new skeleton type, and the inhibiting activity of the Lycojaponicumin B on the Hp is unexpectedly strong, so that no possibility for providing any inspiration by other compounds exists. The Lycojaponicumin B has predominant substantial characteristics and obviously has a remarkable progress in prevention and treatment of Hp infection.
Description
Technical field
The invention belongs to biological pharmacy technical field, particularly relate to Lycojaponicumin B and preparing the application in Anti-helicobacter pylori drugs.
Background technology
Helicobacter pylori (Helicobacter pylori, Hp) is a kind of Gram-negative spiral bacteria.Research display, helicobacter pylori is the primary pathogenic event of acute and chronic gastritis and taste-blindness rate, and may fall ill relevant with gastric cancer stomach function regulating mucosa-associated lymphoid tissue (MALT) malignant lymphoma.Recently, Hp is classified as I class carcinogen by World Health Organization (WHO), and it plays a leading role in stomach cancer development.Simultaneously the scheme that popular at present treatment Hp infects takes the triple therapy that proton pump inhibitor (PPI) adds two kinds of antibiotic (clarithromycin, amoxicillin, tetracycline, metronidazole etc. select two kinds).The main factor affecting triple therapy is considered to the drug resistance of Hp to antibacterial; Another serious problems are that proton pump inhibitor can bring out dyspepsia, and a large amount of antibacterial then causes the serious destruction of flora in digestive tract.Therefore, find the active kind new medicine thing of efficient, safe anti-Hp and become an important and urgent task.
The compound L ycojaponicumin B that the present invention relates to is one and delivers (Wang in 2012, X.J.etal., 2012.Lycojaponicumins A-C, Three Alkaloids with an UnprecedentedSkeleton from Lycopodium japonicum.Organic Letters 14 (10), New skeleton compound 2614-2617.), this compound has brand-new framework types, the purposes of the Lycojaponicumin B that the present invention relates in preparation treatment Anti-helicobacter pylori drugs is belonged to first public, because framework types belongs to brand-new framework types, and it is unexpectedly strong for helicobacter pylori inhibit activities, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control simultaneously for helicobacter pylori infections obviously has significant progress.
Summary of the invention
The object of the invention is the application of research Lycojaponicumin B in Anti-helicobacter pylori drugs.
Described compound L ycojaponicumin B structure is as shown in formula I:
The experiment in vitro of Lycojaponicumin B shows, Lycojaponicumin B has very strong anti Helicobacter pylori activity, and it is 29mm (ATCC43504) that paper disk method shows its antibacterial circle diameter.With agar dilution display, it can suppress the growth of 5 random clinical strains (Hp001, Hp003, Hp004, Hp018 and Hp036) and 1 reference culture (ATCC43504) completely, and minimal inhibitory concentration (MIC) is 1.0 μ g/ml.Make positive control with ampicillin, its Cmin (MIC) suppressed completely 6 strain test bacterium is 0.5 μ g/ml.
This result of study shows, the energy force rate ampicillin of the suppression helicobacter pylori activity of Lycojaponicumin B is strong, illustrate for the diseases such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, Lycojaponicumin B is the compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
The purposes of the Lycojaponicumin B that the present invention relates in preparation treatment Anti-helicobacter pylori drugs belongs to first public, because framework types belongs to brand-new framework types, and it is unexpectedly strong for helicobacter pylori inhibit activities, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control simultaneously for helicobacter pylori infections obviously has significant progress.
Detailed description of the invention
The preparation method of compound L ycojaponicumin B involved in the present invention is see document (Wang, X.J.et al., 2012.Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodiumjaponicum.Organic Letters 14 (10), 2614-2617.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound L ycojaponicumin B tablet involved in the present invention:
Get 20 g of compound Lycojaponicumin B, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound L ycojaponicumin B capsule involved in the present invention:
Get 20 g of compound Lycojaponicumin B, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
The pharmacological evaluation of Lycojaponicumin B
1) strains tested
Helicobacter pylori (Helicobacter pylori, Hp) reference culture ATCC 43504 is purchased from U.S.'s Culture Collection (American Type Culture Collection, ATCC).15 strain Hp clinical strains are picked up from Jiangsu Prov. People's Hospital Gastroenterology dept., clinical laboratory of Jiangsu TCM Hospital and Nanjing Children's Hospital Dndoscope Laboratory and are accepted gastroscopic patient; To the patient of peptic ulcer, duodenal bulbar inflammation or gastritis verrucosa in continuous gastroscopy, first be defined as Hp positive through RUT experiment, get antral gastric mucosa 1-2 block again, be inoculated in containing 8% horse serum, trimethoprim (trimethropin after chopping, in the Columbia selectivity agar culture medium of TMP) 1.25g/L, polymyxin (polymyxin) B2500U/L, vancomycin (vancomycin) 10mg/L, in 37 DEG C of (5%O under micro-oxygen environment
2, 10%CO
2and 85%N
2) cultivate 72 hours.Collect antibacterial, through smear Gram’s staining, after oxidase, catalase and urease are accredited as the positive, pure culture of going down to posterity, obtained strains is as experimental strain.
2) strain culturing
We adopt micro-aerobic bag (purchased from Shanghai Medical Univ) to carry out the strain culturing of HP, and it produces the micro-aerobic environment required for Hp by chemical reaction.
3) biological activity determination
Paper disk method (Microbiological paper method) is adopted to measure the inhibitory action of compound to helicobacter pylori, the minimum inhibitory concentration (minimal inhibitoryconcentration, MIC) of test sample is measured with agar dilution.
I. paper disk method experiment
(A) culture medium is prepared by the Columbia culture medium for preparing after high pressure steam sterilization, be cooled to 50-60 DEG C, add 8% horse serum or Sheep Blood, mixing is poured in the culture dish of sterilizing, every ware 7-10ml, culture medium thickness is 1.5mm (sterile working).
(B) experimental bacteria of transferring (being coated with bacterium) gets diluted 10 with microscale sampler
8cFU/ml (1OD
660=10
8cFU/ml) the bacteria suspension 0.1ml of Hp spreads upon suitable culture dish surface equably.Be inverted in
take out after 15min in drying baker, object makes agar surface dry, for subsequent use.
(C) paste sample scraps of paper microscale sampler to get 6 μ l testing samples (mass concentration 2mg/ml) and inject on the round filter paper of sterilizing.With aseptic nipper tweezer containing the scraps of paper of sample and the blank scraps of paper of contrast, by sterile working respectively the scraps of paper be close to containing bacterio-agar surface, paste a piece of paper sheet at a certain distance.Often kind of bacterium is cooked 3 wares, and acquired results asks its meansigma methods.
(D) each plate is placed in micro-aerobic bag by cultivation, and sealing, opens gas generator, then be placed in
72h is cultivated in incubator.
(E), after surveying antibacterial circle diameter taking-up flat board, the size of antibacterial circle diameter around each scraps of paper is measured respectively.With reference to the result of matched group, the result of testing sample sensitive experiment can be drawn.In triplicate.
II. agar dilution measures MIC
(A) first compound dimethyl sulfoxide (DMSO) solution preparation of test is become the mother solution of 0.5mg/ml by the preparation of Drug plates, then with sterilized water dilution, is finally made into 10.0,8.0,6.0,4.5,4.0,3.5,3.0,2.5,2.0,1.5,1.0, the concentration series of 0.5 and 0.25 μ g/ml, DMSO concentration is in media as well less than 1%.The test compounds solution prepared by 1ml separately adds in the 9ml Columbia medium of 50 DEG C the horse serum that 1ml is incubated in 50 DEG C and fully mixes with being incubated, and casts in culture dish to cool.
(B) experimental bacteria of transferring (being coated with bacterium) draws diluted 1 × 10 with microscale sampler
8the bacteria suspension 0.1ml of CFU/ml Hp spreads upon culture dish surface equably, is inverted in
take out after 15min in drying baker, object makes agar surface dry, for subsequent use.
(C) determine that test dish (contains: 85%N at micro-aerobic bag by MIC
2, 10%CO
2and 5%O
2) in, be incubated 37 DEG C and cultivate 72 hours, observe Hp growing state, contrast with blank group, there is no the sample least concentration of bacteria growing completely for minimum inhibitory concentration (minimal inhibitory concentration, MIC) value.Positive control is ampicillin (Ampicillin).
3, the pharmacological results of Lycojaponicumin B
Experiment in vitro shows, Lycojaponicumin B has very strong anti Helicobacter pylori activity, and it is 29mm (ATCC43504) that paper disk method shows its antibacterial circle diameter.With agar dilution display, it can suppress the growth of 5 random clinical strains (Hp001, Hp003, Hp004, Hp018 and Hp036) and 1 reference culture (ATCC43504) completely, and minimal inhibitory concentration (MIC) is 1.0 μ g/ml.Make positive control with ampicillin, its Cmin (MIC) suppressed completely 6 strain test bacterium is 0.5 μ g/ml.
Conclusion: Lycojaponicumin B suppresses the ability of helicobacter pylori activity only more weak than ampicillin, illustrate for the diseases such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, Lycojaponicumin B is the compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
Claims (1)
1.Lycojaponicumin B is preparing the application in Anti-helicobacter pylori drugs, described compound L ycojaponicumin B structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310435573.2A CN103463023B (en) | 2013-09-23 | 2013-09-23 | Application of Lycojaponicumin B in helicobacter pylori resistant medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310435573.2A CN103463023B (en) | 2013-09-23 | 2013-09-23 | Application of Lycojaponicumin B in helicobacter pylori resistant medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103463023A CN103463023A (en) | 2013-12-25 |
| CN103463023B true CN103463023B (en) | 2015-07-08 |
Family
ID=49788221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310435573.2A Active CN103463023B (en) | 2013-09-23 | 2013-09-23 | Application of Lycojaponicumin B in helicobacter pylori resistant medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463023B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059043A (en) * | 2011-10-24 | 2013-04-24 | 中国医学科学院药物研究所 | Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof |
-
2013
- 2013-09-23 CN CN201310435573.2A patent/CN103463023B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103463023A (en) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111419829B (en) | Application of honokiol in inhibiting streptococcus suis or biofilm thereof | |
| CN102988355A (en) | Application of Aphanamixoid A for preparing helicobacter pylori resistant medicine | |
| CN103463023B (en) | Application of Lycojaponicumin B in helicobacter pylori resistant medicine | |
| CN103446127B (en) | Lycojaponicumin A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103446085B (en) | Incarviatone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103356600B (en) | Chukrasone B is preparing the application in Anti-helicobacter pylori drugs | |
| CN103381165B (en) | Chukrasone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN102861067B (en) | Application of Houttuynoid E in preparing anti-helicobacter pylori (Hp) medicine | |
| CN103690527B (en) | Aphanamgrandiol A is preparing the application in Anti-helicobacter pylori drugs | |
| CN105535171A (en) | Rose tea | |
| CN103550204A (en) | Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments | |
| CN102861055B (en) | Application of Houttuynoid A in helicobacter pylori resisting medicine | |
| CN102872154B (en) | Application of Houttuynoid B in helicobacter pylori resistant medicament | |
| CN102872132B (en) | Application of Houttuynoid D in anti-helicobacter pylori drug | |
| CN105412087A (en) | Application of Parvifloranines A in preparing anti-helicobacter pylori medicine | |
| CN105078970A (en) | Helicobacter pylori medicine and application thereof | |
| CN102872028B (en) | Application of Gypensapogenin A in medicaments against helicobacter pylori | |
| CN102872131B (en) | Application of Houttuynoid C in preparing anti-helicobacter pylori drug | |
| CN105412052A (en) | Application of Micranthanone A in preparing drugs for anti-helicobacter pylori | |
| CN105250259A (en) | Application of Kanshone C to preparation of medicine for resisting helicobacter pylori | |
| CN103356608A (en) | Application of Fluevirosines A in preparing anti-helicobacter pylori medicines | |
| CN105412072A (en) | Application of Rhodomollein XXV in preparation of anti-Hp (anti-Helicobacter pylori) drug | |
| CN103479646A (en) | Application of Kadcoccitones A to in preparation of anti-helicobacter pylori medicament | |
| CN103446117A (en) | Applications of Sarcaboside A in medicament against helicobacter pylori | |
| CN103446104A (en) | Applications of Sarcaboside B in medicament against helicobacter pylori |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171201 Address after: No. 19, Beihai garden shop, No. 99, Yunnan Road, Beihai, the Guangxi Zhuang Autonomous Region Patentee after: Beihai Han Biotechnology Co., Ltd. Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Patentee before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190620 Address after: 536000 Golden Coast Road 45, Beihai, the Guangxi Zhuang Autonomous Region (Beihai hi tech Zone) Patentee after: Wang Xiaoyan Address before: 536011 No. 19 Beihai Garden Shop, 99 Yunnan Road, Beihai City, Guangxi Zhuang Autonomous Region Patentee before: Beihai Han Biotechnology Co., Ltd. |
|
| TR01 | Transfer of patent right |